A New Era in Vaccine Science
For decades, vaccine development has relied on well-established approaches β attenuated viruses, inactivated pathogens, and protein subunits β to train the immune system against disease. While these methods have saved millions of lives, they have inherent limitations in the breadth and durability of the immune responses they can generate. Enter MAPS (Multiple Antigen Presenting System), a revolutionary platform technology that is poised to reshape how we think about immunisation and infectious disease prevention.
At GSK, the quest to get ahead of disease together has led scientists to explore technologies that can elicit both antibody-mediated and T-cell-mediated immunity in a single vaccine construct. MAPS represents one of the most promising advances in this pursuit, combining polysaccharide and protein antigens in a modular framework that can be tailored to target complex pathogens more effectively than traditional approaches.
How MAPS Works: The Science Behind the Platform
The MAPS platform leverages a unique biotinylated polysaccharide backbone that is linked to recombinant protein antigens through a high-affinity biotin-rhizavidin interaction. This creates a macromolecular complex that presents multiple antigens to the immune system simultaneously, mimicking the way the body naturally encounters a pathogen. The result is a coordinated immune response that activates both B cells (for antibody production) and T cells (for cellular immunity).
Key advantages of the MAPS approach include:
- Multivalent antigen presentation: Multiple protein antigens can be attached to the polysaccharide scaffold, enabling broad immune coverage against various strains or serotypes.
- Balanced immune activation: Unlike conventional conjugate vaccines that primarily drive antibody responses, MAPS elicits robust CD4+ and CD17+ T-cell responses alongside high-titre antibodies.
- Modular design: The platform is highly adaptable, allowing researchers to swap antigens in or out to address emerging variants or novel pathogens without redesigning the entire vaccine.
- Thermostability potential: Early data suggest that MAPS constructs may offer improved stability at ambient temperatures, which could transform vaccine distribution in low- and middle-income countries.
From the Laboratory to the Clinic
GSK's investment in MAPS technology reflects a broader commitment to prevention-first healthcare. Clinical studies are evaluating MAPS-based candidates for pneumococcal disease, where the technology's ability to present dozens of serotype-specific polysaccharides alongside conserved protein antigens could deliver superior protection compared to existing vaccines. Early-phase trial results have been encouraging, showing favourable safety profiles and strong immunogenicity across age groups.
Beyond pneumococcal disease, GSK researchers are investigating the platform's applicability to other high-burden infections, including those caused by Staphylococcus aureus and Klebsiella pneumoniae β pathogens for which no licensed vaccines currently exist. The modular nature of MAPS means that once the core platform is validated, it can be rapidly reconfigured to address new threats, a capability that proved critically important during the COVID-19 pandemic.
Impact on Global Health Equity
One of the most compelling aspects of MAPS technology is its potential to address health disparities. Pneumococcal disease remains a leading cause of childhood mortality in sub-Saharan Africa and South-East Asia, and current vaccines, while effective, cover only a subset of circulating serotypes. A MAPS-based vaccine with broader serotype coverage could protect millions of children who are currently underserved by existing immunisation programmes.
GSK's global health strategy, ranked 2nd in the Access to Medicine Index, prioritises equitable access to innovative vaccines. The company is working with international partners including the WHO, Gavi, and the Bill & Melinda Gates Foundation to ensure that next-generation vaccines reach the communities that need them most.
Looking Ahead: The Future of Immunisation
MAPS technology embodies the convergence of immunology, bioengineering, and data science that is driving modern vaccine development. As GSK continues to advance candidates through clinical trials, the platform holds the promise of vaccines that are broader, more durable, and more accessible than anything available today. For patients, healthcare systems, and global health organisations alike, MAPS represents not just a technological breakthrough but a fundamental shift in how we prevent infectious disease.
At a time when antimicrobial resistance and emerging infections pose escalating threats, platform technologies like MAPS offer a powerful tool to stay ahead. By investing in science that can be rapidly adapted to new challenges, GSK is helping to build a world where prevention truly is the best medicine.